Common Stock, $0.01 par value per share
- Symbol
- OCGN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Ocugen, Inc.
OCGNNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On July 13, 2026, Ocugen, Inc. (the “Company”) issued a press release announcing that it signed a binding term sheet for the license of OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Company context
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.
Current securities
Recent company filings
Registered securities in this filing
OCUGEN, INC. · 8-K · Filed 2026-07-13
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On July 13, 2026, Ocugen, Inc. (the “Company”) issued a
press release announcing that it signed a binding term sheet for the license of OCU400 modifier gene therapy for retinitis pigmentosa
in the Middle East and North Africa. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 2 tm2620295d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region. Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to $4 million. The Company would be entitled to sales milestone payments up to $255 million, in …
Open exhibit ↗